Next Article in Journal
Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives
Next Article in Special Issue
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Previous Article in Journal
On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma
Previous Article in Special Issue
ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms
 
 
Article

Article Versions Notes

Cancers 2020, 12(5), 1180; https://doi.org/10.3390/cancers12051180
Action Date Notes Link
article xml file uploaded 7 May 2020 11:58 CEST Original file -
article pdf uploaded. 7 May 2020 11:58 CEST Version of Record https://www.mdpi.com/2072-6694/12/5/1180/pdf-vor
article supplementary file uploaded. 7 May 2020 11:58 CEST - https://www.mdpi.com/2072-6694/12/5/1180#supplementary
article pdf uploaded. 8 May 2020 11:01 CEST Updated version of record https://www.mdpi.com/2072-6694/12/5/1180/pdf-vor
article xml file uploaded 26 May 2020 08:06 CEST Update -
article xml uploaded. 26 May 2020 08:06 CEST Update https://www.mdpi.com/2072-6694/12/5/1180/xml
article pdf uploaded. 26 May 2020 08:06 CEST Updated version of record https://www.mdpi.com/2072-6694/12/5/1180/pdf
article html file updated 26 May 2020 08:08 CEST Original file -
article html file updated 5 June 2020 17:08 CEST Update -
article html file updated 8 October 2020 23:52 CEST Update -
article html file updated 21 July 2022 04:04 CEST Update https://www.mdpi.com/2072-6694/12/5/1180/html
Back to TopTop